These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Therapeutic yield and outcomes of a community teaching hospital code stroke protocol. Asimos AW; Norton HJ; Price MF; Cheek WM Acad Emerg Med; 2004 Apr; 11(4):361-70. PubMed ID: 15064210 [TBL] [Abstract][Full Text] [Related]
31. Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences? Allen NB; Myers D; Watanabe E; Dostal J; Sama D; Goldstein LB; Lichtman JH Cerebrovasc Dis; 2009; 27(3):254-8. PubMed ID: 19176959 [TBL] [Abstract][Full Text] [Related]
32. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. Schwamm LH; Ali SF; Reeves MJ; Smith EE; Saver JL; Messe S; Bhatt DL; Grau-Sepulveda MV; Peterson ED; Fonarow GC Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):543-9. PubMed ID: 24046398 [TBL] [Abstract][Full Text] [Related]
33. Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy. Masrur S; Abdullah AR; Smith EE; Hidalgo R; El-Ghandour A; Rordorf G; Schwamm LH J Stroke Cerebrovasc Dis; 2011; 20(2):124-30. PubMed ID: 20598579 [TBL] [Abstract][Full Text] [Related]
34. Serum creatinine may indicate risk of symptomatic intracranial hemorrhage after intravenous tissue plasminogen activator (IV tPA). Marsh EB; Gottesman RF; Hillis AE; Urrutia VC; Llinas RH Medicine (Baltimore); 2013 Nov; 92(6):317-323. PubMed ID: 24145699 [TBL] [Abstract][Full Text] [Related]
35. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses. Liao X; Wang Y; Pan Y; Wang C; Zhao X; Wang DZ; Wang C; Liu L; Wang Y; Stroke; 2014 Aug; 45(8):2354-8. PubMed ID: 25013020 [TBL] [Abstract][Full Text] [Related]
36. Safety of intravenous thrombolysis in acute ischemic stroke patients with saccular intracranial aneurysms. Mittal MK; Seet RC; Zhang Y; Brown RD; Rabinstein AA J Stroke Cerebrovasc Dis; 2013 Jul; 22(5):639-43. PubMed ID: 22341666 [TBL] [Abstract][Full Text] [Related]
37. Telephonic guidance of systemic thrombolysis in acute ischemic stroke: safety outcome in rural hospitals. Vaishnav AG; Pettigrew LC; Ryan S Clin Neurol Neurosurg; 2008 May; 110(5):451-4. PubMed ID: 18353532 [TBL] [Abstract][Full Text] [Related]
38. The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial. Kamel H; Patel N; Rao VA; Cullen SP; Faigeles BS; Smith WS; Flint AC J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1111-6. PubMed ID: 23122722 [TBL] [Abstract][Full Text] [Related]
39. Current status of intravenous thrombolysis for acute ischemic stroke in Asia. Sharma VK; Ng KW; Venketasubramanian N; Saqqur M; Teoh HL; Kaul S; Srivastava PM; Sergentanis T; Suwanwela N; Nguyen TH; Lawrence Wong KS; Chan BP Int J Stroke; 2011 Dec; 6(6):523-30. PubMed ID: 22111797 [TBL] [Abstract][Full Text] [Related]
40. Barriers to the use of intravenous tissue plasminogen activator for in-hospital strokes. Bunch ME; Nunziato EC; Labovitz DL J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):808-11. PubMed ID: 21640608 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]